Scenarios that move MLTX

MoonLake Immunotherapeutics - Class A Ordinary Shares

Scenarios that move MLTX: 1 analysis, 0 positive, 1 negative.

  1. · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -25 · confidence low · horizon weeks

All scenarios · Run a scenario · Pricing